DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?

Key Points

• DBV Technologies' stock price has fallen below its fifty-day moving average of $9.81, closing at $9.79 with a trading low of $9.61.
• Analysts have mixed views on the stock, with ratings ranging from "strong buy" to "sell" and a consensus price target of $14.75.
• The company reported a quarterly loss of ($1.55) EPS, significantly missing analyst expectations, although revenue surpassed estimates with $1.74 million.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.81 and traded as low as $9.61. DBV Technologies shares last traded at $9.79, with a volume of 13,267 shares changing hands.

Wall Street Analysts Forecast Growth

DBVT has been the subject of several recent research reports. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a report on Thursday, May 29th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. HC Wainwright boosted their price objective on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 5th. Finally, JMP Securities reiterated a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.75.

DBV Technologies Stock Performance

The stock has a market capitalization of $258.56 million, a P/E ratio of -1.98 and a beta of -0.58. The firm has a 50-day moving average price of $9.80 and a 200 day moving average price of $8.10.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. On average, equities analysts anticipate that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently modified their holdings of the company. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies during the 2nd quarter valued at about $340,000. Boxer Capital Management LLC purchased a new stake in DBV Technologies during the 4th quarter valued at about $154,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies during the 2nd quarter valued at about $9,315,000. MPM Bioimpact LLC purchased a new stake in DBV Technologies during the 2nd quarter valued at about $9,649,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies during the 2nd quarter valued at about $9,659,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.